Eledon Pharmaceuticals, Inc. (ELDN)
2.92
-0.07
(-2.34%)
USD |
NASDAQ |
Sep 03, 16:00
2.97
+0.05
(+1.71%)
After-Hours: 20:00
Eledon Pharmaceuticals Research and Development Expense (TTM) : 67.89M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 67.89M |
| March 31, 2026 | 69.93M |
| December 31, 2025 | 66.27M |
| September 30, 2025 | 66.70M |
| June 30, 2025 | 68.26M |
| March 31, 2025 | 58.08M |
| December 31, 2024 | 51.96M |
| September 30, 2024 | 41.10M |
| June 30, 2024 | 32.51M |
| March 31, 2024 | 29.61M |
| December 31, 2023 | 30.31M |
| September 30, 2023 | 30.50M |
| June 30, 2023 | 30.02M |
| March 31, 2023 | 28.56M |
| December 31, 2022 | 27.08M |
| September 30, 2022 | 26.01M |
| June 30, 2022 | 26.22M |
| March 31, 2022 | 24.72M |
| December 31, 2021 | 23.74M |
| September 30, 2021 | 20.59M |
| June 30, 2021 | 13.55M |
| March 31, 2021 | 10.14M |
| December 31, 2020 | 6.131M |
| September 30, 2020 | 4.428M |
| June 30, 2020 | 5.322M |
| Date | Value |
|---|---|
| March 31, 2020 | 6.787M |
| December 31, 2019 | 8.128M |
| September 30, 2019 | 9.535M |
| June 30, 2019 | 9.677M |
| March 31, 2019 | 8.709M |
| December 31, 2018 | 6.817M |
| September 30, 2018 | 4.57M |
| June 30, 2018 | 3.436M |
| March 31, 2018 | 2.64M |
| December 31, 2017 | 2.022M |
| September 30, 2017 | 2.385M |
| June 30, 2017 | 2.921M |
| March 31, 2017 | 2.98M |
| December 31, 2016 | 10.43M |
| September 30, 2016 | 17.31M |
| June 30, 2016 | 24.75M |
| March 31, 2016 | 30.01M |
| December 31, 2015 | 32.64M |
| September 30, 2015 | 28.71M |
| June 30, 2015 | 23.04M |
| March 31, 2015 | 21.58M |
| December 31, 2014 | 14.58M |
| September 30, 2014 | 14.47M |
| June 30, 2014 | 13.10M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.907B |
| Viking Therapeutics, Inc. | 509.32M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |